HER2-Low Should Not Be a Distinct Subtype of Breast Cancer, Researchers Say
There were no significant differences in outcomes between patients with low HER2 expression and those with no HER2 expression, after adjusting for hormone receptor status.
European Society for Medical Oncology (ESMO)
Ceralasertib Provides No Benefit in Advanced Triple-Negative Breast Cancer
Combining ceralasertib with olaparib did not improve response rates or progression-free survival.
Combination Produces Longest Survival to Date in Treatment-Naïve Advanced Breast Cancer
Adding ribociclib to fulvestrant prolonged overall survival by 15.8 months.
Patritumab Deruxtecan Yields Responses in HR+/HER2- Breast Cancer
Patritumab deruxtecan produced “clinically meaningful” responses, according to researchers.
Characterization of Predictors of Response or Resistance to ICIs in NSCLC
PD-L1 expression density and cytotoxic T cells were identified as potential biomarkers for outcomes with ICIs in patients with NSCLC.
Apatinib Plus Gefitinib Improved PFS in EGFR-Mutated NSCLC
The addition of apatinib to gefitinib prolonged PFS compared with gefitinib among treatment-naive patients with EGFR-mutated NSCLC.
No Benefit, Higher Toxicities With Postoperative Conformal RT in Stage IIIAN2 NSCLC
The use of modern postoperative conformal radiotherapy did not improve DFS and was associated with toxicities among patients with stage IIIAN2 NSCLC.
Longitudinal NGS May Identify Patients At Risk for Hyperprogression or Death From ICIs
NGS of longitudinal samples from patients with advanced NSCLC receiving ICIs identified changes associated with hyperprogression and early death.
KRAS Inhibitor Shows Favorable Activity in Advanced NSCLC
Results from a phase 1 trial suggest a KRASG12C inhibitor has a favorable safety profile and antitumor activity in advanced NSCLC.
Characteristics and Treatment Patterns of KRASG12C-Mutated NSCLC
An analysis of from the Flatiron Health Network found that some patients with NSCLC with a KRASG12C mutation do not receive systemic therapy.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ESMO Virtual Congress 2020 Lung Cancer In-depth
Loading... 
Loading...